|
|
Volumn 2, Issue 5, 2001, Pages 205-207
|
|
Withdrawal of cerivastatin from the world market
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ATORVASTATIN;
BEZAFIBRATE;
CERIVASTATIN;
FIBRIC ACID DERIVATIVE;
FLUINDOSTATIN;
GEMFIBROZIL;
HIGH DENSITY LIPOPROTEIN CHOLESTEROL;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
MEVINOLIN;
PLACEBO;
PRAVASTATIN;
SIMVASTATIN;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG APPROVAL;
DRUG EFFICACY;
DRUG FATALITY;
DRUG MARKETING;
DRUG SAFETY;
DRUG WITHDRAWAL;
HUMAN;
KIDNEY FAILURE;
MORTALITY;
RHABDOMYOLYSIS;
RISK BENEFIT ANALYSIS;
|
|
EID: 0034752421
PISSN: 14686708
EISSN: None
Source Type: Journal
DOI: 10.1186/CVM-2-5-205 Document Type: Article |
|
Times cited : (343)
|
|
References (11)
|
